4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Net Margin came in at 2256.65% in Q1 2026, up 34040050.0% year-on-year from N/an in Q1 2025, and down 9999.37% on a QoQ basis from 22.8% in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Net Margin data on file, last reported at 2256.65% in Q1 2026.
- On a quarterly basis, Net Margin rose 34040050.0% year-over-year to 2256.65% in Q1 2026; TTM through Mar 2026 was 182.34%, a 76694375.0% increase from a year earlier, with the FY2025 full-year figure at 164.43%, up 43461395.0% from the prior year.
- Net Margin for Q1 2026 stood at 2256.65%, down from 22.8% in the prior quarter.
- Over the last five years, Net Margin for FDMT reached as high as 169910.53% in Q4 2023 and fell as low as 4967100.0% in Q4 2024.
- Historically, Net Margin has averaged 464398.39% across 5 years, with a median of 12391.63% in 2023.
- Across the five-year window, Net Margin tumbled 513701053 bps in 2024 and surged 496712280 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 2195.59% in 2022, then jumped by 7839 bps to 169910.53% in 2023, then tumbled by 3023 bps to 4967100.0% in 2024, then jumped by 100 bps to 22.8% in 2025, then sank by 9999 bps to 2256.65% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 2256.65% in Q1 2026, 22.8% in Q4 2025, and 63195.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -2,256.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,256.65% |
| Dec 31, 2025 | 22.80% |
| Sep 30, 2025 | -63,195.56% |
| Jun 30, 2025 | -364,386.67% |
| Mar 31, 2025 | -342,657.14% |
| Dec 31, 2024 | -4,967,100.00% |
| Sep 30, 2024 | -1,461,433.33% |
| Jun 30, 2024 | -699,060.00% |
| Mar 31, 2024 | -115,717.86% |
| Dec 31, 2023 | 169,910.53% |
| Sep 30, 2023 | -50.76% |
| Jun 30, 2023 | -12,391.63% |
| Mar 31, 2023 | -9,624.83% |
| Dec 31, 2022 | -2,195.59% |
| Sep 30, 2022 | -5,138.20% |
| Jun 30, 2022 | -17,337.04% |
| Mar 31, 2022 | -2,160.62% |
| Dec 31, 2021 | -27,264.13% |
| Sep 30, 2021 | -1,628.04% |
| Jun 30, 2021 | -52.05% |